On July 23, 2024, according to Japanese media news, KOBAYASHI PHARMACEUTICAL Company released a report of external experts investigating the response to health damage related to health products containing monascus ingredients.

The report noted that despite the recognition of penicillium attachment in the monascus culture tank, the manufacturing site was left unchecked. In addition, it was found that even after learning about kidney disease cases, doctors answered that they had no side effects. Outside experts have criticized KOBAYASHI's practice of lagging in informing consumers.

In addition, the report alleges that KOBAYASHI's Chairman Kazuya Kobayashi and President Akihiro Kobayashi failed to exercise sufficient leadership and failed to make judgments and give instructions that would have ensured the safety of consumers.KOBAYASHI PHARMACEUTICAL decided at an interim board meeting on July 23 that the two top management executives would resign.

As of July 21, the number of suspected deaths under investigation for causation, including those initially announced, totaled 101.